ADPT
Adaptive Biotechnologies Corporation (ADPT) Scenario Analysis Analysis (2026)
Overall Score
Base Case
ADPT continues to screen as a high-gross-margin but unprofitable business, with gross margin at 75.4% and net margin at -20.7%.
Liquidity remains strong with a current ratio of 4.79 and cash per share of 2.18, supporting near-term operating flexibility.
Valuation remains elevated at 13.7x EV/Sales despite negative free cash flow and negative EBITDA, implying the market still prices in meaningful future improvement.
Bull Case
If revenue growth and operating leverage improve, the company could convert its strong gross margin into sustainable profitability.
The balance sheet and liquidity profile provide room to invest in growth without immediate financing pressure.
A return to positive operating cash flow would materially improve the upside case given the current negative cash generation.
Bear Case
Persistent negative EBITDA (-5.2% margin) and free cash flow yield (-0.6%) keep execution risk elevated.
High valuation leaves little margin for error if growth slows or profitability takes longer to emerge.
Interest coverage remains negative at -3.26x, underscoring that current operating losses are not yet covered by earnings.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Adaptive Biotechnologies Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

